These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Alencar AKN; Montes GC; Barreiro EJ; Sudo RT; Zapata-Sudo G Front Pharmacol; 2017; 8():858. PubMed ID: 29255415 [TBL] [Abstract][Full Text] [Related]
9. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP? Koress C; Swan K; Kadowitz P Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316 [TBL] [Abstract][Full Text] [Related]
10. Loss of smooth muscle cell hypoxia inducible factor-1α underlies increased vascular contractility in pulmonary hypertension. Barnes EA; Chen CH; Sedan O; Cornfield DN FASEB J; 2017 Feb; 31(2):650-662. PubMed ID: 27811062 [TBL] [Abstract][Full Text] [Related]
18. Treating pulmonary arterial hypertension: current treatments and future prospects. Raja SG; Raja SM Ther Adv Chronic Dis; 2011 Nov; 2(6):359-70. PubMed ID: 23251761 [TBL] [Abstract][Full Text] [Related]
19. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension. Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276 [TBL] [Abstract][Full Text] [Related]